David Urech (file photo)
March 9, 2020 04:39 AM EDTUpdated 09:22 AM
Financing

Mit­subishi joins Ei­sai, 3SBio's bet on mul­ti­spe­cif­ic an­ti­bod­ies, up­ping Num­ab's Se­ries B haul to $23M+

Amber Tong

Fol­low­ing a busy year of deal­mak­ing, Swiss an­ti­body shop Num­ab has closed a Se­ries B at CHF22 mil­lion ($23.87 mil­lion) to dou­ble down on its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times